ClinicalTrials.gg
Not yet recruitingNCT07434973STEP-PROMOTEUpdated Oct 8, 2026

Stratification and Treatment in Early Psychosis Study - PROMOTE

A Phase 3 interventional study of Cannabidiol (CBD) and Placebo in Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis and Clinical High Risk for Developing Psychosis, sponsored by University of Oxford. Not yet recruiting at 19 sites in 10 countries. Open to participants aged 12 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Oxford · Phase 3, Interventional, and Treatment

How we know

Updated Oct 8, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.

Planned enrollment
Largest of 11
586 · median 64
Started
2026
with 1 other
Phase 3
4 of 11
4 open now
Registered
11th of 11
by date
Lead sponsor
3 of 11
University of Oxford

Among the 11 studies testing cannabidiol in Psychotic Disorders, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 11th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cannabidiol in Psychotic Disorders, or all of them as a file.
02

Study summary

The purpose of this trial is:

  • To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
  • To confirm the safety of CBD in individuals at clinical high risk for psychosis.

The trial is a randomised, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals meeting clinical high risk for psychosis criteria will be recruited for the trial intervention component of the trial. Participants are randomised to treatment with oral CBD 300mg (oral solution 100 mg/mL) twice daily, or a matching placebo, for 104 weeks. By using a battery of clinical outcome assessments, the trial will be able to assess several biomarkers to predict clinical outcomes and response to treatment with CBD. Participants will be invited to provide blood samples, stool samples, cerebrospinal fluid samples (if aged 18 years or over) and complete neuroimaging assessments. Individuals who are not found to have mental illness as defined by DSM-5 criteria will be recruited to a healthy control group, to validate the biomarker component of the trial.

Additionally, a control group of healthy volunteers will be recruited who will not take the trial intervention to aid calibration between datasets from sites acquiring MRI data and to inform and validate any possible multivariate signature associated with the CHR-P state, course or outcome by understanding how these measures are different in controls. Healthy controls will also be used for secondary case-control comparisons. Healthy controls will undergo clinical and biomarker assessments only.

03

Conditions studied

  • Clinical High Risk for Psychosis (CHR)
  • Clinical High Risk for Psychosis
  • Clinical High Risk for Developing Psychosis

Browse trials for

Keywords

  • STEP-PROMOTE
  • PROMOTE
  • CHR-P
  • Clinical High Risk for Psychosis
  • psychosis
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

CHR-P patients:

Inclusion Criteria

  1. 12 to 35 years of age inclusive, willing and able to provide written /assent.
  2. Meet criteria for either the Attenuated Psychotic Symptoms (APS) or Brief Limited Intermittent Psychotic Symptoms (BLIPS) subgroups of the CHR-P state, defined using the CAARMS (PSYSCAN version), which also integrates the SIPS criteria. Inter-rater reliability will be ensured throughout via an ongoing training programme for the researchers at each site.
  3. The participant is currently not participating and is not expecting to start participation during the current trial in another intervention trial (e.g. medication, medical device, psychological intervention).
  4. Participants of * must be willing to ensure that they use highly effective during the trial as per the requirements in the protocol**
  5. For participants who take part in the optional MRI scans: they must be eligible for MRI scanning as per local requirements, for example concerning implants or braces.
  6. For participants who take part in optional CSF collection: they must be aged 18 years or over, have excluded intracranial hypertension through MRI, be within the reference ranges in coagulation tests, have a ≤32kg/m2, and have no medical or surgical conditions in which a lumbar puncture is .

The age range for eligibility has been applied as this corresponds to the usual age range for a clinical high-risk state; individual cases outside of this age range may have a different aetiology and/or prognosis which could impact on the trial outcomes.

There is inadequate information on the effects of cannabidiol on the foetus in humans. Participants of childbearing potential* should use a highly effective method of contraception** for the duration of the trial and for 3 months after the last time the trial intervention was used. There is no special requirement for male participants to use highly effective contraception as there are no known safety concerns in males, such as sperm toxicity, as per the investigator's brochure. This trial will also not be collecting male participant partner pregnancy data.

*A person is considered of childbearing potential, i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

** Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: 1) combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral; intravaginal; transdermal); 2) progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; implantable); 3) intrauterine device (IUD); 4) intrauterine hormone-releasing system (IUS); 5) bilateral tubal occlusion; 6) vasectomised partner; 7) sexual abstinence (abstinence should only be used as a contraceptive method if it is in line with the participants' usual and preferred lifestyle).

Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The participant agrees to use an acceptable method of contraception for the duration of the trial and for 3 months after any trial drug administration, unless surgically sterile or postmenopausal (no menses for 12 months without an alternative medical cause).

Exclusion Criteria

  1. Previous neurosurgery or neurological disorder, including epilepsy, which may affect the trial procedures;*
  2. Pregnancy or breastfeeding;
  3. The participant is unable to fully comprehend the purpose of the trial or make a rational decision whether or not to participate;
  4. IQ\<70 as measured by a validated IQ test e.g. WASI, WAIS, WISC, as approved for local languages and appropriate for the participant's age;
  5. Meeting criteria for substance use disorder, with the exception of nicotine use disorder (mild, moderate, and severe allowed). Mild cannabis use disorder is allowed (i.e. can meet up to but no more than 3 criteria on the SCID-5-RV) as long as the subject has not consumed cannabis on average more than three times a week in the past 30 days. Mild alcohol use disorder is also allowed;
  6. Antipsychotic exposure: any antipsychotic medication in the two weeks before screening at doses adequate for treating FEP (≥ minimum effective dose); or antipsychotic medication for longer than a cumulative total of 30 days in the 3 months before screening at doses adequate for treating FEP (≥ minimum effective dose);**
  7. Any past episode of frank psychosis (excluding BLIPS);
  8. to the active substance, sesame oil, sesame seed, or any of the listed in section 3.3 of the IB;
  9. Current treatment with valproate (including valproic acid, sodium valproate, valproate semisodium);
  10. Current treatment with clobazam;
  11. Known hepatic insufficiency and/or transaminase levels exceeding the upper limit 2 times or more and greater than 1.5 times the ;
  12. Active suicidal ideation within the past 2 weeks (a score of 1 or higher on CDSS question 8, followed by an assessment by the treating clinician who determines it is not safe for the patient to participate in the trial) or presence of risk (e.g. violence) ***;
  13. The participant has participated in another research study in which the participant received an experimental or drug or intervention within 3 months before Visit 0;
  14. The participant refuses or cannot do any mandatory safety checks during the trial, specifically, refusal of: pregnancy test (those of childbearing potential only); safety blood tests; reporting of adverse events; or assessment of suicidality;
  15. Those of childbearing potential not willing to use a highly effective form of contraception during participation in the trial. There is inadequate information on the effects of cannabidiol on the foetus. Participants of childbearing potential should use a highly effective method of contraception for the duration of the main trial and for 3 months after any administration of trial intervention;
  16. Traumatic brain injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument.

    • Minor neurological disorders such as migraine, other minor headache disorders, sleep disorders or nerve palsies that are unlikely to affect trial or biomarker outcomes can be permitted.

      • If at screening, a potential participant is prescribed an antipsychotic at a dose ≥ minimum effective dose for treating FEP, they may be re-screened for trial participation at a later date if the dose is subsequently reduced below threshold for at least 2 weeks. Any decision to do so will be the responsibility of the treating clinician and must ensure that it is both safe and ethical to do so. Specialist advice will be made available and be provided by clinicians experienced in managing CHR-P at University of Oxford and King's College London.

        • The decision to include the patient is at the clinician's discretion. In case of a score of 1 or higher in CDSS question 8, the clinician can conclude that it is safe for the patient to participate after the patient is evaluated, in which case this exclusion criterion does not apply and the patient can participate. Either way, the treating clinician needs to record his/her evaluation of suicidal risk in the source documentation or medical file, including his/her considerations, and notify the site PI of the decision.

Healthy controls:

Inclusion Criteria

  1. 12 to 35 years old;
  2. Written informed consent/assent;
  3. Be assessed for the CHR-P state but do not meet CHR-P criteria: Attenuated Psychotic Symptoms (APS) or Brief Limited Intermittent Psychotic Symptoms (BLIPS) defined using the CAARMS;
  4. Be assessed with the SCID-5-RV and do not meet any diagnostic criteria of any Axis I psychiatric disorder.

Exclusion Criteria

  1. Lifetime history of a DSM Axis-I psychiatric disorder as determined by the SCID-5-RV;
  2. Lifetime history of meeting CHR-P state criteria;
  3. First-degree relative with a lifetime history of affective or non-affective psychosis (defined by treatment or diagnosis);
  4. Previous intake of antipsychotic medication at any dosage;
  5. Current intake of psychoactive medication;
  6. Previous neurosurgery or neurological disorder, including epilepsy, which may affect the trial procedures;
  7. Pregnant or breastfeeding;
  8. Participant is unable to fully comprehend the purpose of the trial or make a rational decision whether or not to participate;
  9. IQ\<70 as measured by a validated IQ test e.g. WASI, WAIS, WISC, as approved for local languages and appropriate for the participant's age;
  10. Any contraindications for MRI;
  11. Refusing to have their blood drawn and/or their MRI performed.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
586 participants (estimated)

Study arms

  • Active comparator
    Cannabidiol 100g/ml oral solution

    Participants will take the intervention for 106 weeks (104 weeks plus a 2-week taper). Doses depend on age and weight: Adults (16 years and older) over 50kg: daily dose 600mg (6ml); 300mg (3ml) twice a day (b.i.d); Adults (16 years and older) less than 50kg: daily dose 10mg/kg; 5mg/kg twice a day (b.i.d); Children (\<16 years old): daily dose 5mg/kg twice a day (b.i.d), following on from a two-week rapid titration schedule. n=188

    Drug: Cannabidiol (CBD)

  • Placebo comparator
    Placebo

    Participants will take the intervention for 106 weeks (104 weeks plus a 2-week taper). Doses depend on age and weight: Adults (16 years and older) over 50kg: daily dose 600mg (6ml); 300mg (3ml) twice a day (b.i.d). Adults (16 years and older) less than 50kg: daily dose 10mg/kg; 5mg/kg twice a day (b.i.d). Children (\<16 years old): daily dose 5mg/kg twice a day (b.i.d), following on from a two-week rapid titration schedule. n=188

    Drug: Placebo

  • No intervention
    Healthy controls

    A healthy control in the context of this trial is someone who does not meet CHR-P criteria or have a diagnosis of a mental health condition. They will not take the trial intervention and attend one trial visit for clinical assessments and biomarker sampling only. n=150

Interventions

06

What researchers measure

Primary outcomes

  1. ChaChange from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score)

    Change from baseline to Week 104 in the positive symptom subscale score (P1-P4) of the Comprehensive Assessment of At-Risk Mental States (CAARMS). Higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 104

Secondary outcomes

  1. Change in attenuated psychotic symptoms (Comprehensive Assessment of At-Risk Mental States, CAARMS total score)

    Change from baseline to Week 4 in CAARMS (Comprehensive Assessment of At-Risk Mental States) total score

    Time frame: Baseline to Week 4

  2. Change in attenuated psychotic symptom subscale scores (Comprehensive Assessment of At-Risk Mental States, CAARMS P1-P4)

    Change from baseline to Week 4 in Comprehensive Assessment of At-Risk Mental States (CAARMS) P1-P4 subscale scores.

    Time frame: Baseline to Week 4

  3. Change in distress associated with attenuated psychotic symptoms

    Change from in Comprehensive Assessment of At-Risk Mental States (CAARMS) distress scores.

    Time frame: Baseline to Week 4

  4. Change in anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A)

    Change from baseline to Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score.

    Time frame: Baseline to Week 4

  5. Change in anxiety symptoms (Overall Anxiety Severity and Impairment Scale, OASIS)

    Change from baseline to Week 4 in Overall Anxiety Severity and Impairment Scale (OASIS) score

    Time frame: Baseline to Week 4

  6. Remission from Clinical High-Risk for Psychosis (CHR-P) state

    Proportion of participants meeting Comprehensive Assessment of At-Risk Mental States (CAARMS) remission criteria at Week 4.

    Time frame: Baseline to Week 4

  7. Change in quality of life (EQ-5D-3L index score)

    Change from baseline to Week 4 in EQ-5D-3L index score.

    Time frame: Baseline to Week 4

  8. Change in quality of life (WHOQOL-BREF total score)

    Change from baseline to Week 4 in WHOQOL-BREF total score.

    Time frame: Baseline to Week 4

  9. All-cause treatment discontinuation

    Proportion of participants who discontinue study treatment for any reason by Week 4.

    Time frame: Baseline to Week 4

  10. Incidence of adverse events

    Number of participants with one or more adverse events by Week 4.

    Time frame: Baseline to Week 4

  11. Severity of adverse events (Glasgow Antipsychotic Side-effect Scale, GASS total score)

    Change from baseline to Week 4 in Glasgow Antipsychotic Side-effect Scale (GASS) total score.

    Time frame: Baseline to Week 4

  12. Change in clinician-rated global severity (Clinical Global Impressions (CGI) scale- - Severity, CGI-S)

    Change from baseline to Week 4 in Clinical Global Impressions scale- - Severity (CGI-S) score.

    Time frame: Baseline to Week 4

  13. Change in clinician-rated global severity (Clinical Global Impressions (CGI) scale- - Improvement, CGI-I)

    Change from baseline to Week 4 in Clinical Global Impressions scale- - Improvement (CGI-I) score.

    Time frame: Baseline to Week 4

  14. Change in patient-rated global severity (Patient Global Imression of Improvement, PGI-I)

    Change from baseline to Week 4 in Patient Global Imression of Improvement (PGI-I) score.

    Time frame: Baseline to Week 4

  15. Change in patient-rated global severity (Patient Global Impression of Severity, PGI-S)

    Change from baseline to Week 4 in Patient Global Imression of Severity (PGI-S) score.

    Time frame: Baseline to Week 4

  16. Change in attenuated psychotic symptoms (Comprehensive Assessment of At-Risk Mental States, CAARMS total score)

    Time frame: Baseline to Week 104

  17. Change in attenuated psychotic symptom subscale scores (Comprehensive Assessment of At-Risk Mental States, CAARMS P1-P4)

    Time frame: Baseline to Week 104

  18. Change in anxiety symptoms (Hamilton Anxiety Rating Scale , HAM-A)

    Time frame: Baseline to Week 104

  19. Change in anxiety symptoms (Overall Anxiety Severity and Impairment Scale, OASIS)

    Time frame: Baseline to Week 104

  20. Change in global functioning (Social and Occupational Functioning Assessment Scal, SOFAS)

    Time frame: Baseline to Week 104

  21. Change in cognitive functioning (PsyCog battery composite score)

    Time frame: Baseline to Week 104

  22. Transition to psychosis

    Proportion of participants meeting Comprehensive Assessment of At-Risk Mental States (CAARMS) criteria for transition to psychosis. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline to Week 104

  23. Remission from Clinical High-Risk for Psychosis (CHR-P) state

    Time frame: Baseline to Week 104

  24. Change in quality of life (EQ-5D-3L)

    Time frame: Baseline to Week 104

  25. Change in quality of life (WHOQOL-BREF)

    Time frame: Baseline to Week 104

  26. All-cause treatment discontinuation

    Time frame: Baseline to Week 104

  27. Incidence of adverse events

    Time frame: Baseline to Week 104

  28. Severity of adverse events (Glasgow Antipsychotic Side-effect Scale, GASS)

    Time frame: Baseline to Week 104

  29. Change in clinician-rated global impression (CGI)

    Time frame: Baseline to Week 104

  30. Change in patient-rated global impression (PGI)

    Time frame: Baseline to Week 104

  31. Diagnosis of mental disorders

    Proportion of participants diagnosed with a mental disorder based on clinical record review. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline, Week 104, and 4 years post-baseline

  32. Prescription of psychotropic medication

    Proportion of participants prescribed psychotropic medication. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline, Week 104, and 4 years post-baseline

  33. Psychiatric hospital or emergency department admission

    Proportion of participants admitted to psychiatric hospital or emergency services. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline, Week 104, and 4 years post-baseline

  34. Number of healthcare appointments

    Total number of healthcare appointments recorded. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline to 4 years post-baseline

  35. Mortality (including suicide)

    All-cause mortality, including suicide. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.

    Time frame: Baseline to 4 years post-baseline

  36. Change in environmental risk score (Psychosis Polyrisk Score, PPS)

    Time frame: Baseline to Week 104

  37. Change in psychopathology (Semi-structured Interview for Bipolar At Risk States, SIBARS score)

    Time frame: Baseline to Week 104

  38. Change in psychopathology (Young Mania Rating Scale, YMRS score)

    Time frame: Baseline to Week 104

  39. Change in borderline personality features (McLean Screening Instrument for borderline personality disorder, MSI-BPD score)

    Time frame: Baseline to Week 104

  40. Change in daily functioning (Functional Remission of General Schizophrenia, FROGS score)

    Time frame: Baseline to Week 104

  41. Change in physical activity (Simple Physical Activity Questionnaire, SIMPAQ score)

    Time frame: Baseline to Week 104

  42. Change in resilience (Resilience Scale for Adults, RSA score)

    Time frame: Baseline to Week 104

  43. Change in substance use (Alcohol, Smoking and Substance Involvement Screening Tool, ASSIST score)

    Time frame: Baseline to Week 104

07

Study locations

19 sites
08

References and documents

Individual participant data

Plan to share: Yes — Please contact the sponsor, who will provide instructions for submitting a data request. All data can be requested, regardless of the location of the requesting party.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data and supporting documents will become available once the primary papers are available in the scientific domain.

Access criteria: These will be provided by the sponsor to the requesting party.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 26 phase 3 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 72. This study's planned 36 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 27, 2026
StartEst.
Dec 1, 2026was May 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→Dec 1, 2026
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Start date May 1, 2026→Dec 1, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07434973
Collaborators
Wellcome Trust, Jazz Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Jared Robinson
Contact
steptrials@phc.ox.ac.uk
+44 7900206137
Jennifer Davies
Contact
steptrials@phc.ox.ac.uk
Philip McGuire, PhD, MD
principal investigator · University of Oxford

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion